Home » Newsletters » BioWorld Science

BioWorld Science

May 14, 2010

View Archived Issues

Novel extended-release, tamper-resistant formulation of oxycodone shows favorable PK

Merck KGaA identifiies novel oral heat shock protein 90 inhibitors for cancer

Novartis claims novel farnesyl pyrophosphate synthase inhibitors

Boehringer Ingelheim discloses novel 11beta-HSD1 inhibitors

UCB presents novel PI3K inhibitors

Novel KCNQ2/3 channel modulators claimed by Gruenenthal scientists

GlaxoSmithKline describes novel antibacterial agents

FDA requires more data before approving naproxcinod NDA for osteoarthritis

Viralytics set to meet with FDA to review proposed phase II melanoma study

Nymox reports safety monitoring committee update for phase III NX-1207 trials

Capstone Therapeutics continues second phase II AZX-100 trial

Resverlogix completes dosing in phase II ASSERT trial ahead of schedule

Soligenix completes enrollment in phase II trial of orBec in acute GVHD prevention

NexMed presents preclinical results for Vitaros in wound healing

Omeros selects clinical candidate for MASP-2 antibody program

PLx Pharma receives multiple grants from the NIH for developing safer NSAIDs

VGX-100 enhances antitumor effects of bevacizumab/docetaxel in vivo

Preclinical data support safety and potent antitumor activity of C-BiTE antibody

TransVax CMV vaccine safe and immunogenic up to 1 year in HSCT patients

Idenix Pharmaceuticals reports interim phase II and other data on anti-HCV treatments

Boston Scientific obtains E.U. approval for Taxus Element Stent System

Rabeprazole treatment beneficial in patients with functional dyspepsia

FDA approves IND application for AEZS-108 in bladder cancer

Pfizer to acquire Ergonex Pharma's investigational treatment for PAH

RegeneRx receives NIH grant for development of its heart attack drug RGN-352

GSK and Dong-A enter strategic alliance to copromote their products in South Korea

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...